Synthesis of novel triplet drugs with 1,3,5-trioxazatriquinane skeletons and their pharmacologies. 1: Synthesis of triplet drugs with morphinan skeletons.
暂无分享,去创建一个
[1] P. Portoghese,et al. A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm. , 2011, ACS medicinal chemistry letters.
[2] K. Palczewski. Oligomeric forms of G protein-coupled receptors (GPCRs). , 2010, Trends in biochemical sciences.
[3] H. Nagase,et al. Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration. , 2010, Bioorganic & medicinal chemistry letters.
[4] L. Miller,et al. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization. , 2010, Journal of medicinal chemistry.
[5] M. Waldhoer,et al. Opioid-receptor-heteromer-specific trafficking and pharmacology. , 2010, Current opinion in pharmacology.
[6] H. Nagase,et al. Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative. , 2009, Bioorganic & medicinal chemistry.
[7] H. Mochizuki,et al. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. , 2009, Drugs of today.
[8] H. Nagase,et al. Novel synthesis of a 1,3,5-trioxazatriquinane skeleton using a nitrogen clamp. , 2009, Organic letters.
[9] M. Narita,et al. Synthesis of novel twin drug consisting of 8-oxaendoethanotetrahydromorphides with a 1,4-dioxane spacer and its pharmacological activities: mu, kappa, and putative epsilon opioid receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.
[10] H. Nagase,et al. Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists. , 2008, Bioorganic & medicinal chemistry.
[11] H. Nagase,et al. Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. , 2008, Bioorganic & medicinal chemistry letters.
[12] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[13] C. Hague,et al. Heterodimerization of G Protein-Coupled Receptors: Specificity and Functional Significance , 2005, Pharmacological Reviews.
[14] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[15] B. O'dowd,et al. Oligomerization of opioid receptors: generation of novel signaling units. , 2002, Current opinion in pharmacology.
[16] L. Devi,et al. G-protein-coupled receptor dimerization: modulation of receptor function. , 2001, Pharmacology & therapeutics.
[17] H. Nagase,et al. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. , 1998, Chemical & pharmaceutical bulletin.
[18] F. Gibson,et al. The structure of enterochelin and related 2,3-dihydroxy-N-benzoylserine conjugates from Escherichia coli. , 1970, Biochimica et biophysica acta.
[19] J. Neilands,et al. Enterobactin, an iron transport compound from Salmonella typhimurium. , 1970, Biochemical and biophysical research communications.
[20] H. Nagase,et al. Synthesis of novel basic skeletons derived from naltrexone. , 2011, Topics in current chemistry.
[21] H. Fujii. Twin and triplet drugs in opioid research. , 2011, Topics in current chemistry.
[22] H. Brockmann,et al. Valinomycin I, XXVII. Mitteil. über Antibiotica aus Actinomyceten , 1955 .